Testing SYS6010 vs chemo for advanced EGFR-mutated lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called SYS6010 compared to standard chemotherapy for people with EGFR-mutated lung cancer that has stopped responding to pill treatments. It may offer a new option if your current EGFR TKI is no longer working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have advanced non-small cell lung cancer (NSCLC) with an EGFR mutation.
- You have already tried at least one EGFR TKI pill (like gefitinib, erlotinib, or osimertinib) and it stopped working.
- You have not had chemotherapy for advanced lung cancer before.
- Your cancer can be seen on a CT or MRI scan (at least one measurable tumor spot).
- You are in good enough health to be up and about (ECOG score 0 or 1) and your organs are working well.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination therapy (DZD6008 plus other drugs) for people with advanced lung cancer that has an EGFR mutation and has stopped responding to a third-generation targeted therapy. It aims to find a better treatment option for these patients.
This trial tests a new drug called SSGJ-706, either alone or with other treatments, for people with advanced non-small cell lung cancer (NSCLC) that has spread or cannot be surgically removed. The goal is to see if it helps shrink or control the cancer.
This trial tests a new drug called SYS6010 combined with osimertinib for people with advanced non-small cell lung cancer that has specific EGFR mutations. It aims to see if this combination works better than current treatments.
This trial tests a new drug called SYS6010 against a standard chemotherapy (docetaxel) for people with a certain type of advanced lung cancer that does not have an EGFR mutation and has stopped responding to previous treatments. The goal is to see which treatment works better.
This trial tests whether a new drug combination (SYS6010 plus enlonstobart) works better than standard immunotherapy with chemotherapy for patients with advanced non-small cell lung cancer. You may qualify if you have not received prior cancer treatment and have a specific marker (PD-L1) on your tumor.
This trial tests a new drug called SYS6010 against standard chemotherapy in people with advanced breast cancer that has a specific protein (EGFR) but not the HER2 protein. It is for those whose cancer has come back or spread and who have already had some chemotherapy.
Hear when a new EGFR-mutated Locally Advanced or Metastatic NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.